US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist

5.560
+0.140+2.58%

Close Feb 28 16:00 ET

5.600
+0.040+0.72%

Post 20:01 ET

249.03MMarket Cap-10.30P/E (TTM)

Y-mAbs Therapeutics Stock Forum

Jaguar8

Jan 10 06:35

NEWS

$Y-mAbs Therapeutics (YMAB.US)$
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
11 seconds ago, 4:35 AM PST
Via GlobeNewswire
YMAB
Share
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appo...

Jaguar8

Dec 8, 2024 18:55

NEWS SATURDAY

$Y-mAbs Therapeutics (YMAB.US)$
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...

Trytosaveabit

Dec 8, 2024 15:51

Watching Monday/week 12/9! Data released Saturday and more to come Monday 12/9/24

$Y-mAbs Therapeutics (YMAB.US)$ Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Moomoo AI

Mar 24, 2024 10:01

Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Moomoo AI

Mar 3, 2024 08:57

The company's cash runway and revenue growth are positive. Its cash burn relative to market capitalisation is low, indicating potential for more cash raising with minimal dilution or borrowing. The company's cash burn is not a concern, suggesting it is well-positioned for continued growth funding.